Clinical evidence from an exploratory proteogenomic analysis of the CANTOS trial demonstrates that IL-1β inhibition with canakinumab not only improved hemoglobin levels in patients with CH mutations and anemia, but also suppressed hepcidin, proinflammatory cytokines, and myeloid activation pathways [169]. Here, HAMP is linked to cyclic hematopoiesis.